InsidersTradesSigma
Track the BIO-TECHNE Corp stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, BIO-TECHNE Corp has published 190 reports. Market capitalisation: €11.3bn. The latest transaction was disclosed on 18 August 2026 (Levée d'options). Among the most active insiders: Kelderman Kim. Every trade is accessible without an account.
190
Insider Decl.
n/a
Thresholds
€100,413
1 ops.
Buy Volume
€14m
12 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BIO-TECHNE Corp Hold (neutral), based on 11 analysts. Average price target: US$70.73.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 13,724 of 29,063 companies
53.5
score / 100
Value34
Quality73
FCF yld2.3%
Earn yld1.6%
EV/EBITDA33.4x
ROE9.0%
Gross mgn66%
Net mgn15%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations190 total
589 shares0Common StockSEC:0000914190-26-000113:0
213 shares@ US$72.40Common StockSEC:0000914190-26-000113:1
5,423 shares0Common StockSEC:0000914190-26-000114:0
1,947 shares@ US$72.40Common StockSEC:0000914190-26-000114:1
4,350 shares0Common StockSEC:0000914190-26-000116:0
1,343 shares@ US$72.40Common StockSEC:0000914190-26-000116:1
6,416 shares0Common StockSEC:0000914190-26-000120:0
1,976 shares@ US$72.40Common StockSEC:0000914190-26-000120:1
9,779 shares0Common StockSEC:0000914190-26-000121:0
4,310 shares@ US$72.40Common StockSEC:0000914190-26-000121:1
21,470 shares0Common StockSEC:0000914190-26-000122:0
10,821 shares@ US$72.40Common StockSEC:0000914190-26-000122:1
51,024 shares@ US$72.030.033% mcap11.9% of flowCommon StockSEC:0000914190-26-000108:1
62,068 shares@ US$47.600.027% mcap9.6% of flowCommon StockSEC:0000914190-26-000108:0
28,686 shares@ US$72.070.019% mcap15.5% of flowCommon StockSEC:0000914190-26-000106:1
35,000 shares@ US$47.600.015% mcap12.5% of flowCommon StockSEC:0000914190-26-000106:0
344 shares@ US$71.770.0002% mcap21.9% of flowCommon StockSEC:0000914190-26-000104:1
448 shares@ US$47.600.0002% mcap18.9% of flowCommon StockSEC:0000914190-26-000104:0
600 sharesCommon StockSEC:0000914190-26-000096:0
216 shares@ US$49.770.0001% mcap38.8% of flowCommon StockSEC:0000914190-26-000096:1
311 shares@ US$55.020.0002% mcap100.0% of flowCommon StockSEC:0000914190-26-000083:1
794 sharesCommon StockSEC:0000914190-26-000083:0
62,000 shares0Common StockSEC:0000914190-26-000080:0
11,344 shares0Common StockSEC:0000914190-26-000081:0
56,097 shares@ US$58.580.029% mcap15.2% of flowCommon StockSEC:0000914190-26-000080:1
25 of 190 declarations
关于 BIO-TECHNE Corp
BIO-TECHNE Corp（股票代码：TECH）是一家总部位于美国的生命科学公司，在美国纳斯达克上市。对于法国、比利时和瑞士的法语投资者而言，Bio-Techne 作为一家高质量的工具和诊断产品供应商脱颖而出，其业务涵盖基础研究、转化生物学和精准诊断。该公司总部位于明尼苏达州，通过34个分支机构在全球运营，拥有约3,100名员工。其产品组合包括超过500,000种产品，涵盖试剂、生物活性蛋白、分析仪器和诊断解决方案。（[bio-techne.com](https://www.bio-techne.com/about/about-bio-techne?utm_source=openai)） Bio-Techne 是生命科学工具行业中一家历史悠久的特许经营公司；该公司表示将在2026年庆祝成立50周年，这突显了其在生物医学研究工具领域的悠久运营历史。随着时间的推移，它凭借广泛的产品目录和专业的科学知识，在学术实验室、生物制药客户和临床诊断用户中建立了公认的地位。其产品深度和科学声誉是市场中的关键差异化因素，在这个市场中，信任、可重复性和检测性能至关重要。（[investors.bio-techne.com](https://investors.bio-techne.com/press-releases/detail/533/bio-techne-releases-third-quarter-fiscal-2026-results?utm_source=openai)） 该公司的业务模式围绕三个面向客户的品牌组织：用于试剂和生物活性蛋白的R&D Systems、用于空间生物学的Bio-Techne Spatial以及用于诊断和临床工作流程的Bio-Techne Diagnostics。这种结构反映了其覆盖从发现到转化研究和临床决策的整个科学路径的深思熟虑的战略。Bio-Techne 还强调了Ella等平台以及不断增长的空间生物学和蛋白质组学分析产品，从而增强了其对高价值、创新驱动型终端市场的敞口。（[bio-techne.com](https://www.bio-techne.com/about/about-bio-techne?utm_source=openai)） 从竞争角度来看，Bio-Techne 受益于其在试剂和检测方面的优质品牌、庞大的装机量以及在制药、生物技术和学术界多元化的客户组合。其业务并非不受生物技术融资周期的影响，但该公司最近表示，大型制药公司的需求具有弹性，美国学术市场趋于稳定，而新兴生物技术客户则持续保持谨慎。这种组合使该股票具有平衡的特征：结构上具有吸引力的长期增长，但短期内对研究支出趋势敏感。（[investors.bio-techne.com](https://investors.bio-techne.com/press-releases/detail/533/bio-techne-releases-third-quarter-fiscal-2026-results?utm_source=openai)） 近期新闻头条主要关注投资组合优化和产品创新。Bio-Techne 完成了其外泌体诊断业务的剥离，推出了简化的品牌架构，并在Ella自动化台式平台上推出了新的超灵敏检测方法。管理层还强调了生产力和成本控制措施，同时继续投资于空间生物学和蛋白质组学等关键增长支柱。总的来说，Bio-Techne 似乎正在将其投资组合精简为更高增长、更高利润的科学工具和诊断产品，这对于寻求在美国纳斯达克医疗保健和制药领域获得投资机会的投资者而言具有重要意义。（[investors.bio-techne.com](https://investors.bio-techne.com/press-releases/detail/513/bio-techne-releases-first-quarter-fiscal-2026-results/?utm_source=openai)）
